

A New Cassane-type Diterpene and Other Constituents from *Caesalpinia minax*Huiling Liu,<sup>a</sup> Guoxu Ma,<sup>a</sup> Jingquan Yuan,<sup>†</sup> Xiaoming Tan,<sup>‡</sup> Qingxia Zheng, Zhaocui Sun, Junshan Yang, and Xudong Xu<sup>\*</sup>

Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China. \*E-mail: xdxu@implad.ac.cn

<sup>†</sup>National engineering laboratory of southwest endangered medicinal resources development, National Development and Reform Commission, Guangxi Botanical Garden of Medicinal Plant, Nanning, China

<sup>‡</sup>Guangxi Botanical Garden of Medicinal Plant, Guangxi Key Laboratory of Medicinal Resources Conservation and Genetic Improvement, Nanning 530023, China

Received October 30, 2012, Accepted February 11, 2013

**Key Words :** Fabaceae, *C. minax*, Cassane-type diterpenes, Lasiodiplodin


*Caesalpinia minax* Hance (Fabaceae) is a medicinal plant growing in the tropical and subtropical regions of southeast Asia. Its seeds, known as “kushilian”, have been long used in Chinese traditional medicine for the treatment of dysentery and sore diseases.<sup>1</sup> Recent studies showed that the cassane-type diterpenes of genus *Caesalpinia* displayed significant biological activities such as antimalarial,<sup>2</sup> antibacterial,<sup>3</sup> antihelmintic,<sup>4</sup> antiproliferative and antineoplastic activities.<sup>5,6</sup> As a part of our exploration on the medicinal plant, the CHCl<sub>3</sub> extract of the seeds of this plant was studied. One new cassane-type diterpene, named 1 $\alpha$ ,7 $\beta$ -diacetoxy-5 $\alpha$ -hydroxy-12 $\alpha$ -methoxycass-13(15)-en-16,12-olide-17 $\beta$ -carboxylate, along with ten known compounds (Figure 1) were isolated. In this paper, we report the isolation and structure elucidation of the new compound.

Compound **1** was isolated as a white amorphous powder with a  $[\alpha]_D^{20}$  as  $-12.0$  ( $c = 0.1$ , MeOH). HR-ESI-MS gave a

quasi-molecular ion peak at  $m/z$  531.2191  $[M + Na]^+$  (Calcd 531.2206) in the positive-ion mode. In conjunction with the analyses of <sup>1</sup>H and <sup>13</sup>C-APT (Table 1) spectra, the molecular formula of compound **1** was deduced as C<sub>26</sub>H<sub>36</sub>O<sub>10</sub>. The IR spectrum showed hydroxyl absorption at 3479 cm<sup>-1</sup> and carbonyl absorption at 1738 cm<sup>-1</sup> (lactone). The UV absorption maximum was 202 nm along with the IR absorption band at 1738 cm<sup>-1</sup>, indicating the presence of an  $\alpha,\beta$ -


**Table 1.** NMR data (600 MHz) for compounds **1** in CDCl<sub>3</sub>

Position	$\delta_C$ , type	$\delta_H$ (J in Hz)
1	74.9, CH	4.86 s
2	22.9, CH <sub>2</sub>	1.72-1.76, m 1.92-1.99, m
3	30.1, CH <sub>2</sub>	1.13-1.17, m 1.76-1.80, m
4	38.6, C	
5	78.4, C	
6	32.4, CH <sub>2</sub>	1.56-1.60, m 2.02-2.05, m
7	74.8, CH	5.21, m
8	44.1, CH	2.21-2.23, m
9	36.0, CH	2.81, td (10.8, 2.4)
10	43.6, C	
11	36.1, CH <sub>2</sub>	1.53-1.58, m 2.15-2.17, m
12	106.8, C	
13	163.1, C	
14	48.9, CH	3.18, d (10.8)
15	118.0, CH	5.81, s
16	168.7, C	
17	171.0, C	
18	28.1, CH <sub>3</sub>	1.02, s
19	24.7, CH <sub>3</sub>	1.11, s
20	17.7, CH <sub>3</sub>	1.03, s
1-O $\underline{C}$ OCH <sub>3</sub>	169.9, C	
1-OC $\underline{O}$ CH <sub>3</sub>	21.4, CH <sub>3</sub>	2.00, s
7-OC $\underline{O}$ CH <sub>3</sub>	169.2, C	
7-OC $\underline{O}$ CH <sub>3</sub>	21.3, CH <sub>3</sub>	2.11, s
14-COO $\underline{C}$ H <sub>3</sub>	52.3, CH <sub>3</sub>	3.78, s
12-OC $\underline{H}$ <sub>3</sub>	50.7, CH <sub>3</sub>	3.16, s



**Figure 1.** Structures of Compounds **1-11**.

<sup>a</sup>These authors contributed equally to this work.



**Figure 2.** HMBC correlations of compound **1**.

butenolide ring.<sup>7</sup> The olefinic proton signal at  $\delta_{\text{H}}$  5.81 (s, H-15) and olefinic carbon signals at  $\delta_{\text{C}}$  118.0 (C-15), 163.1 (C-13) also confirmed the presence of an  $\alpha,\beta$ -butenolide ring, combined with the three methyl signals at  $\delta_{\text{H}}$  1.02 (s, H<sub>3</sub>-18), 1.03 (s, H<sub>3</sub>-20), 1.11 (s, H<sub>3</sub>-19) which are typical signals for cassane-type diterpenes. Therefore, the basic skeleton of **1** was cassane diterpenoid lactone-type. The data above were similar to those of 1 $\alpha,7\beta$ -diacetoxy-5 $\alpha,12\alpha$ -dihydroxy-cass-13(15)-en-16,12-olide-17 $\beta$ -carboxylate (**9**),<sup>14</sup> except for the hydroxy group in **9** which was replaced by methoxy group in **1**. All carbon-bond protons were assigned from HSQC spectrum. The HMBC correlations (Figure 2) observed between  $\delta_{\text{H}}$  4.86 (s, H-1) and  $\delta_{\text{C}}$  169.9 (1-OCO), between  $\delta_{\text{H}}$  5.21 (m, H-7) and  $\delta_{\text{C}}$  169.2 (7-OCO), between  $\delta_{\text{H}}$  3.18 (d,  $J=10.6$ , H-14),  $\delta_{\text{H}}$  3.78 (s, 14-COOCH<sub>3</sub>) and  $\delta_{\text{C}}$  171.0, and between  $\delta_{\text{H}}$  3.16 (s, 12-OCH<sub>3</sub>) and  $\delta_{\text{C}}$  106.8 indicated that the acetyl groups were at C-1 and C-7, carboxymethyl group at C-14 and methoxy group at C-12. The relative configuration of compound **1** was determined on the basis of NOESY spectrum. The NOEs from H<sub>3</sub>-20 to H-1 ( $\delta_{\text{H}}$  4.86, s), H-8 ( $\delta_{\text{H}}$  2.21-2.23, m), H-11<sub>ax</sub> ( $\delta_{\text{H}}$  2.15-2.17, m) and H<sub>3</sub>-19 ( $\delta_{\text{H}}$  1.11, s), from H<sub>3</sub>-18 to H-7 ( $\delta_{\text{H}}$  5.21, m), H-9 ( $\delta_{\text{H}}$  2.81, td,  $J=10.8, 2.4$ ), and from H-9 to 12-OCH<sub>3</sub> ( $\delta_{\text{H}}$  3.16 s), H-14 ( $\delta_{\text{H}}$  3.18 d,  $J=10.8$ ) indicated that rings A and B have a chair conformation with *trans*-fused ring junction and thus confirmed the relative configuration at C-1, C-7, C-10, C-12 and C-14. The circular dichroism (CD) showed a strong negative cotton effect with the  $\gamma$ -lactone chromophore at  $\lambda_{\text{max}}$  232 nm indicated that the chirality at C-12 was *R*.<sup>8</sup> Combined with the NOESY spectrum, compound **1** was characterized as 1 $\alpha,7\beta$ -diacetoxy-5 $\alpha$ -hydroxy-12 $\alpha$ -methoxycass-13(15)-en-16,12-olide-17 $\beta$ -carboxylate.

The known compounds were identified as 6 $\beta$ -hydroxy-neocaesalpin E (**2**),<sup>9</sup> Neocaesalpin W (**3**),<sup>10</sup> Neocaesalpin C (**4**),<sup>11</sup> Neocaesalpin J (**5**),<sup>12</sup> 12,16-epoxy-5 $\alpha$ -hydroxy-12 $\alpha$ -methoxycassa-13-(15)-en-16-one (**6**),<sup>13</sup> Neocaesalpin N (**7**),<sup>12</sup> 12 $\alpha$ -ethoxyl-1 $\alpha,6\alpha,7\beta$ -triacetoxy-5 $\alpha,14\beta$ -dihydroxy-cass-13(15)-en-16,12-olide (**8**),<sup>14</sup> 1 $\alpha,7\beta$ -diacetoxy-5 $\alpha,12\alpha$ -dihydroxy-cass-13(15)-en-16,12-olide-17 $\beta$ -carboxylate (**9**),<sup>14</sup> 7 $\beta$ -acetoxy-6 $\beta$ -hydroxyneocaesalpin E (**10**)<sup>9</sup> and lasiodiplo-din (**11**).<sup>15</sup> Among them, compounds **2-4**, **6** and **10** were reported for the first time from this plant and compound **11** has not been reported in any species of the genus *Caesalpinia*.

### Experimental Section

**Plant Material.** The seeds of *C. minax* were collected in September 2008 from Nanning, Guangxi Province, China and identified by Prof. Jing-Quan Yuan, Department of Pharma-

ceutical Chemistry, Guangxi Botanical Garden of Medicinal Plant. A voucher specimen (NO. 21648) was deposited at the Guangxi Botanical Garden of Medicinal Plant, Nanning, Guangxi province, China.

**1 $\alpha,7\beta$ -Diacetoxy-5 $\alpha$ -Hydroxy-12 $\alpha$ -Methoxycass 13 (15)-en-16,12-olide-17 $\beta$ -Carboxylate (**1**):** white amorphous powder.  $[\alpha]_{\text{D}}^{20} -12.0$  ( $c=0.1$  MeOH); IR (KBr)  $\text{cm}^{-1}$  3479, 1738  $\text{cm}^{-1}$ ; UV  $\lambda_{\text{max}}$  (MeOH) nm (log  $\epsilon$ ): 202 (3.49); CD (MeOH,  $\Delta\epsilon$ )  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 232 (-6.87) nm; <sup>1</sup>H and <sup>13</sup>C-NMR (CDCl<sub>3</sub>): see Table 1; HR-ESI-MS  $m/z$ : 531.2191 [M + Na]<sup>+</sup> (Calcd for 531.2206).

**Acknowledgments.** The work was supported by the technological large platform for comprehensive research and development of new drugs in the Eleventh Five-Year "Significant New Drugs Created" Science and Technology Major Projects (No. 2009ZX09301-003). National Natural Science Foundation of China (No. 30973626), Innovation Capacity-building in Guangxi Science and Technology Agency (No. 10100027-3), National Science and technology support program (No. 2012BA127B06), Guangxi science and technology achievements transformation project (No. 1298009-22), Nanning Science Research and Technology Development Program (No. 201102088C). And the publication cost of this paper was supported by the Korean Chemical Society.

**Supporting Information.** General experimental procedures, the isolation details and spectra data of compound **1** are available as Supporting Information.

### References

- He, S. Z. *Chinese Traditional and Herbal Drugs*. **2000**, 31, 226.
- Kalauni, S. K.; Awale, S.; Tezuka, Y.; Banskota, A. H.; Linn, T. Z.; Asih, P. B. S.; Syafruddin, D.; Kadota, S. *Biol. Pharm. Bull.* **2006**, 29, 1050.
- Dickson, R. A.; Houghton, P. J.; Hylands, P. J. *Phytochemistry* **2007**, 68, 1436.
- Jabbar, J.; Zaman, M. A.; Iqbal, Z.; Yaseen, M.; Shamima, A. *J. Ethnopharmacol.* **2007**, 114, 86.
- Hou, Y.; Cao, S.; Brodie, P.; Miller, J. S.; Birkinshaw, C.; Ratovoson, F.; Rakotondrajaona, R.; Andriantsiferana, R.; Rasamison, V. E.; Kingston, D. J. *J. Nat. Prod.* **2008**, 71, 150.
- Yadav, P. P.; Maurya, R.; Sarkar, J.; Arora, A.; Kanojia, S.; Sinha, S.; Srivastava, M. N.; Raghur, R. *Phytochemistry* **2009**, 70, 256.
- Kinoshita, T.; Haga, Y.; Narimatsu, S.; Shimada, M.; Goda, Y. *Chem. Pharm. Bull.* **2005**, 53, 717.
- Matsuno, Y.; Deguchi, J.; Hirasawa, Y.; Ohyama, K.; Toyoda, H.; Hirobe, C.; Ekasari, W.; Widyawaruyanti, A.; Zaini, N. C.; Morita, H. *Bioorg. Med. Chem. Lett.* **2008**, 18, 3774.
- Cheng, J.; Roach, J. S.; Mclean, S.; Reynolds, W. F.; Tinto, W. F. *Nat. Prod. Commun.* **2008**, 3, 1751.
- Wu, Z. H.; Wang, Y. Y.; Huang, J.; Sun, B. H.; Wu, L. *J. Asia J. of Traditional Medicines* **2007**, 2, 135.
- Kinoshita, T. *Chem. Pharm. Bull.* **2000**, 48, 1375.
- Li, D. M.; Ma, L.; Liu, G. M.; Hu, L. H. *Chem. Biodiversity* **2006**, 3, 1260.
- Roach, J. S.; Mclean, S.; Reynolds, W. F.; Tinto, W. F. *J. Nat. Prod.* **2003**, 66, 1378.
- Wu, Z. H.; Huang, J.; Li, W. D.; Wu, L. J.; Gao, H. Y. *J. of Asian Nat. Prod. Res.* **2010**, 12, 781.
- Wang, H. S.; Wang, Y. H.; Shi, Y. N.; Li, X. Y.; Long, C. L. *China Journal of Chinese Materia Medica* **2009**, 34, 414.